Drug intelligence / Profile preview

JMJT-HT11

Development stage: Preclinical
Lead developer: Jianmin Pharmaceutical Group

Overview

JMJT-HT11 is an investigational drug candidate currently in preclinical development by Jianming Pharmaceutical Group (also known as Wuhan Jianmin Pharmaceutical) for the treatment of infertility. As a pipeline-stage asset, specific details regarding its chemical structure, molecular target, and pharmacological modality (such as whether it is a small molecule or a biological agent) have not been publicly disclosed. The program is currently undergoing CMC (Chemistry, Manufacturing, and Controls) and preclinical safety and efficacy evaluations to support potential future clinical trials. It is part of Jianming's broader research and development efforts in reproductive health and modern Chinese medicine.

Beyond the preview

Go deeper on JMJT-HT11.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JMJT-HT11.

Explore the full profile